Lilly suspends late-stage trials of diabetes drug Protege
Eli Lilly and partner MacroGenics suspended trials of their investigational type I diabetes drug Protege after it failed to meet its primary endpoint.
Protege (teplizumab), a humanised, anti-CD3 monoclonal antibody, was being trialled to promote immune tolerance in type I diabetics.
http://www.inpharm.com/news/101022/lilly-suspends-late-stage-trials-diabetes-drug-protege
Eli Lilly and partner MacroGenics suspended trials of their investigational type I diabetes drug Protege after it failed to meet its primary endpoint.
Protege (teplizumab), a humanised, anti-CD3 monoclonal antibody, was being trialled to promote immune tolerance in type I diabetics.
http://www.inpharm.com/news/101022/lilly-suspends-late-stage-trials-diabetes-drug-protege
